Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?

导出 OA

翻译打印收藏纠错

作者： Wout,De Wispelaere ^[1] ; Daniela,Annibali ^[1] ; Sandra,Tuyaerts ^[2] ; Diether,Lambrechts ^[1] ; Frédéric,Amant ^[3]

作者单位： Department of Oncology, KU Leuven (University of Leuven) and Leuven Cancer Institute (LKI), 3000 Leuven, Belgium. ^[1] Division of Oncogenomics, Antoni Van Leeuwenhoek-Netherlands Cancer Institute (AvL-NKI), 1066 CX Amsterdam, The Netherlands. ^[2] Laboratory of Medical and Molecular Oncology (LMMO), Department of Medical Oncology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), 1090 Brussels, Belgium. ^[3] Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven (University of Leuven), 3000 Leuven, Belgium. ^[4] VIB Center for Cancer Biology, Flemish Institute for Biotechnology (VIB), 3000 Leuven, Belgium. ^[5] Centre for Gynecologic Oncology Amsterdam (CGOA), Antoni Van Leeuwenhoek-Netherlands Cancer Institute, University Medical Center (UMC), 1066 CX Amsterdam, The Netherlands. ^[6] Department of Obstetrics and Gynecology, University Hospitals Leuven (UZ Leuven), 3000 Leuven, Belgium. ^[7]

关键词 combinatorial treatment strategies high-risk gynecological tumors immune checkpoint blockade resistance uterine leiomyosarcoma

DOI 10.3390/cancers13092040

PMID 33922556

发布时间 2021-05-18

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交